Beyond skin-deep: The role of topical calcineurin inhibitors in the treatment of atopic dermatitis
17 Aug 2017
The prevalence of atopic dermatitis (AD) in industrialized countries has increased exponentially over the past three decades, currently affecting 15 to 30% of children and up to 10% of adults.1 At the recent official launch event of pimecrolimus (Elidel®, Meda Healthcare Sdn. Bhd.) held at Le Méridien Kuala Lumpur, Professor Thomas Luger provided insights on the pathophysiology of AD and the role of topical calcineurin inhibitors (TCIs) in the management of AD.
Related MIMS Drugs